Health Disparities - Open Grant Opportunities

College of Health Sciences
Office of Research

Sponsor	Name of Program	Deadline	Brief Description	Opportunity ID
National Institutes of Health https://grants.nih.gov/grants/guide/pa-files/PAR-18-287.html	Health Services Research on Minority Health and Health Disparities (R21 Clinical Trial Optional) **Mechanism** R21	4 /11/2019	The purpose of this Funding Opportunity Announcement (FOA) is to encourage innovative exploratory and developmental health services research to improve minority health and/or reduce health disparities at the health care system-level as well as within clinical settings.	638
National Institutes of Health https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-18-043.html	Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R01 Clinical Trial Not **Mechanism** R01	6 /11/2019	The purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and validation of novel therapeutic targets to facilitate the development of pain therapeutics. Specifically, the focus of this FOA is on the basic science discovery of targets in the peripheral nervous system, central nervous system, immune system or other tissues in the body that can be used to develop treatments that have minimal side effects and little to no abuse/addiction liability. Research supported by this FOA must include rigorous validation studies to demonstrate the robustness of the target as a pain treatment target. This will lower the risk of adopting the target in translational projects to develop small molecules, biologics, natural substances, or devices that interact with this target for new pain treatments. Translational research to develop new medical devices is not the focus of this FOA. Basic science studies of pain and related systems in the body are responsive to this FOA and are encouraged in the context of novel pain therapeutic target discovery. This FOA is not specific for any one or group of pain conditions. Projects to identify novel targets for acute pain, chronic pain, migraine, other headache disorders, osteoarthritis, diabetic neuropathy, chemotherapy-induced neuropathy, sickle-cell pain, post stroke pain, orofacial pain, etc. will be considered. Projects to identify novel targets for a combination of chronic overlapping pain conditions or for specific pathological conditions will be considered. Projects that seek to identify novel targets in specific populations such as women, children, older adults or other underrepresented groups will also be responsive to this FOA. LOI due 10/27/18; application due 11/27/18.	837

Sponsor	Name of Program	Deadline	Brief Description	Opportunity ID
National Institutes of Health	Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R21 Clinical Trial Not **Mechanism** R21	6 /11/2019	This program announcement is intended to encourage new exploratory and developmental research projects to discover and validate novel targets for pain treatment. For example, such projects could assess the feasibility of a means to identify and validate a novel pain target. Another example could include the unique and innovative use of an existing methodology to explore an area of basic biology that could lead to the discovery of a novel pain treatment target. In any scenario, initial experiments to validate a target for pain treatment should be included in the application. These studies may involve considerable risk but may lead to a breakthrough in pain treatment. The focus of this FOA is on the basic science discovery of targets in the peripheral nervous system, central nervous system, immune system or other tissues in the body that can be used to develop treatments that have minimal side effects and little to no abuse/addiction liability. Research supported by this FOA must include rigorous validation studies to demonstrate the robustness of the target as a pain treatment target. This will lower the risk of adopting the target in translational projects to develop small molecules, biologics, natural substances, or devices that interact with this target for new pain treatments. Translational research to develop new medical devices are not the focus of this FOA. Basic science studies of pain and related systems in the body are responsive to this FOA and are encouraged in the context of novel pain therapeutic target discovery. This FOA is not specific for any one or group of pain conditions. Projects to identify novel targets for acute pain, chronic pain, migraine, other headache disorders, osteoarthritis, diabetic neuropathy, chemotherapy-induced neuropathy, sickle-cell pain, orofacial pain, post stroke pain, etc. will be considered. Projects to identify novel targets for a combination of chronic overlapping pain conditions or for specific pathological conditions will be considered. Projects that seek to identify novel targets in specific populations such as women, children, older adults or other underrepresented groups will also be responsive to this FOA. LOI due 10/27/18; application due 11/27/18.	834

https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-18-042.html

Total Number of Opportunities **3**